December 16, 2024
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

December 13, 2024
2024 Report on TB Research Funding Trends
TB R&D Report
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.

December 13, 2024
TB R&D Funding: Billions Short and Reliant on a Few Major Donors, New Report Finds
Statement / Press
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.

December 9, 2024
Cheat Sheets for Tuberculosis Activists
Publication
TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.

November 26, 2024
Community Trainings on Drug-Resistant TB
Webinar / Presentation
To help advocates stay up to date, Treatment Action Group (TAG) organized a series of virtual trainings on the diagnosis, treatment, care and support of people with drug-resistant TB, designed for community and civil society organizations.

November 26, 2024
TAGline November 2024
TAGline
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.

November 25, 2024
1/4/6×24 Campaign Concerned Prices Hinder Uptake of Important Updated World Health Organization Drug-Resistant TB Treatment Recommendations
Statement / Press
The 1/4/6×24 Campaign warns that regimens to treat drug-resistant TB recently recommended by World Health Organization (WHO) and important diagnostic tools will remain out of reach due to high prices.

November 20, 2024
2024 TAG Update
Publication
As we approach the end of 2024, we want to share with you some of the remarkable progress we’ve made together, and you’ll see some of our work in the 2024 TAG Update.

November 13, 2024
Finally, Children of All Ages Can Benefit from 3HP to Prevent TB!
Statement / Press
The Community Research Advisors Group (CRAG) celebrates both the findings and the methodology of Study 35, a phase I/II clinical trial of the tuberculosis (TB) preventive treatment regimen known as 3HP in children.

November 11, 2024
TAG Statement on the Global Fund and Other Funding Sources to Fight TB, HIV, and Other Pandemics
Statement / Press
In advance of the 52nd Meeting of the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) and the 2024 Union World Conference on Lung Health, Treatment Action Group (TAG) releases this statement in response to ongoing conversations about the Global Fund’s program allocations for HIV, tuberculosis (TB), and malaria.

October 29, 2024
Statement from TAG’s TB Project on Today’s WHO Global TB Report Release
Statement / Press
Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization’s 2024 Global Tuberculosis Report.

October 8, 2024
Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short
Statement / Press
TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

September 25, 2024
Statement on the UN High Level Meeting on Antimicrobial Resistance Final Draft Political Declaration
Statement / Press
Treatment Action Group (TAG) congratulates Malta and Barbados, co-facilitators, and all United Nations (UN) Member States participating in the High-Level Meeting on Antimicrobial Resistance (AMR) upon the publication of the final draft of the Political Declaration.

September 16, 2024
2024 Research in Action Awards Celebrate Leaders in Global Health Activism Who Exemplify TAG’s Mission
Statement / Press
Treatment Action Group’s (TAG) most important fundraising event of the year is the Research in Action Awards, which honor the best and brightest activists, researchers, leaders, and scientists whose work has been integral in ending HIV, tuberculosis (TB), and hepatitis C (HCV).

August 14, 2024
Treatment Action Group Calls for Coordinated, Fully Funded Global Response to Mpox Emergency
Statement / Press
Treatment Action Group (TAG) supports the World Health Organization (WHO) in declaring the renewed outbreak of mpox a public health emergency of international concern.

July 25, 2024
TAG Calls for Universal Access to Innovative HCV Testing to End the Disease by 2030
Statement / Press
This World Hepatitis Day, July 28, we are better positioned than ever to end hepatitis C Virus (HCV) as a pandemic.

July 25, 2024
Three New Members Elected to TAG’s Board of Directors
Statement / Press
Treatment Action Group (TAG) elected three new members to its Board of Directors in May 2024. Board President Ivy Kwan Arce said, “TAG is reinvigorating its Board in alignment with our vision, mission, and values.

July 18, 2024
2024 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

July 17, 2024
2023 Annual Report
Publication
We’re pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.

June 26, 2024
Call For New Global TB CAB Members
On behalf of the Global Tuberculosis Community Advisory Board (TB CAB), we’re excited to announce a call for new member applications.

June 26, 2024
TAG Calls on Danaher to Drop the Prices of GeneXpert Tests and Make the Cost Audit Public
Statement / Press
Treatment Action Group (TAG) calls on Danaher to lower the price of GeneXpert tests for tuberculosis (TB) and other diseases to $5 each in accordance with publicly available evidence of the cost of manufacturing and to commit to public transparency of the cost audit of Xpert MTB/RIF Ultra.

June 20, 2024
An Open Letter to Médecins Sans Frontières — Urgent Call to Reverse the Devastating Decision to Shutter the MSF Access Campaign
Letter / Comment
TAG’s emergency plea to our allies at MSF to preserve its life-saving and world-changing MSF Access Campaign (Campaign for Access to Essential Medicines) — we need them now more than ever!

June 20, 2024
Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions
Statement / Press
Treatment Action Group (TAG) welcomes the news that the long-acting injectable HIV capsid inhibitor lenacapavir has proven efficacious at preventing HIV acquisition among young women and adolescent girls in South Africa and Uganda.

June 11, 2024
Frequently Asked Questions on Microarray Patches (MAPs)
Publication
Microarray patches (MAPs) are arrays of microneedles that stick to your skin like a bandage, offering a noninvasive mechanism for drug administration.

May 30, 2024
Comments Delivered at the WHO Director-General’s TB Vaccine Accelerator Council
Letter / Comment
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 2nd meeting of the WHO Director-General’s TB Vaccine Accelerator Council in Geneva Switzerland.